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Abstract
Background: The Italian and European Best Practice Guidelines (EBPG) recommend a target
haemoglobin value greater than 11 g/dl in most patients with Chronic Kidney Diseases. However,
it is still difficult to maintain these values at a steady rate. Thus, the main aim of the study was to
evaluate, throughout 2005, how many patients steadily maintained the performance targets related
to anaemia treatment.
Methods: The survey was conducted on 3283 patients on haemodialysis (HD) and peritoneal
dialysis (PD) at 20 Italian dialysis centres. 540 patients were randomly selected; each centre
provided a statistically significant sample proportional to its total number of patients. Maintenance
of the following target levels was assessed over time: Haemoglobin (HB) 11-12 gr/dl; Iron: 60-160
mcg/dl; Ferritin: 30-400 mcg/l; Transferrin: 200-360 mg/dl; Transferrin saturation percentage
(TSAT %):> 25 <50; Dialysis doses (KT/V): >1.2 <2.0 for non-diabetic HD patients; >1.5 <2.2 for
diabetic HD patients; DP: >1.8 <2.5.
Outcome included:
1- Percentage of target maintenance for each parameter.
2- Erythropoietin dose in relation to dialysis techniques, presence of cancer or myeloma, diabetic
status, Vitamin B therapy.
3- Erythropoietin dose (International Units/kg/week) (IU/kg/wk) depending on: haemoglobin values,
hospitalization of more than 3 days.
Results: Mean age was 65.1; mean haemoglobin concentration over the whole population was 11.3
gr/dl (Standard Deviation (SD): 0.91). The clinical performance targets were maintained over time
as follows: HB: 4.3% (Mean 11.43 gr/dl) (SD: 0.42); Ferritin: 71.1% (Mean: 250.23 mcg/L
(SD:104.07); Iron: 95.0% (Mean 59.79 mcg/dl)(SD:16.76); Transferrin: 44.8% (Mean 216.83 mg/dl)
(SD: 19,50); TSAT %: in 8.4% (Mean: 34.33% (SD: 6.56); HD KT/V: 61.0% (Mean:1.46) (SD: 0.7); PD
KT/V:31.4% (Mean: 2.10) (SD: 0.02). The average weekly dose of Erythropoietin (IU/Kg/Wk) was
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significantly lower for the peritoneal dialysis technique; the higher haemoglobin values, the lower
the Erythropoietin dose (IU/Kg/Wk).
Conclusion: A very low percentage of patients maintained haemoglobin target values over time.
We need to identify precise criteria to evaluate the stability over time of clinical performance
targets proposed by the guidelines.
Background
Achieving and maintaining stable Haemoglobin levels is
a clinical performance target for monitoring the quality
and outcome of care in patients undergoing chronic dial-
ysis.
The European Best Practice Guidelines 2004 [1,2] and
Italian Guidelines 2003 [3,4] recommend that most
patients with Chronic Kidney Diseases (CKD) achieve a
target Haemoglobin (Hb) of ≥ 11 gr/dl to reduce the risk
of adverse outcomes [5]. The optimal upper Hb level has
not been determined [6,7]. Hb target values in the range
of 11-12 gr/dl are recommended by the majority of guide-
lines of other countries, but not all [8-11]. However the
current evidence for choosing the minimum Hb target
value of 11 gr/dl is very limited. As Kidney Disease
Improving Global Outcomes (KDIGO) has yet to publish
the new guidelines on anaemia treatment, the European
guidelines have maintained the aforementioned target.
Recent studies indicate that Haemoglobin values fluctuate
over time [12-15] and that several parameters contribute
to Hb cycling, such as: inflammatory or infectious disease
processes[16], illness and hospitalisation, fluid balance,
iron status and therapy [14,17], Erythropoiesis-stimulat-
ing agents (ESAs) dose adjustment [18], management
practices and laboratory variation and error [19-21];
moreover, previous studies have yet to pinpoint how to
predict the individual response to ESA treatment. Recent
studies have also demonstrated that while average Hb lev-
els may fall within desired targets, Hb levels are not con-
sistently maintained within a specified target range over
time [13,14,16,22]; furthermore, data indicates that fail-
ing to control Hb levels over time may increase the risk of
adverse outcomes, including mortality [23-29].
A number of studies have demonstrated the difficulties
involved in maintaining Hb levels within a narrow target
range. The studies, carried out over variable time periods,
involved patients with Chronic Kidney Disease (CKD) in
5th stage conservative therapy [30], or incident or preva-
lent HD patients [14,16,31]. As simple methods for eval-
uating and comparing the achievement of performance
targets have yet to be standardized, it is difficult to assess
their stability in unselected populations of dialysis
patients.
For the purpose of evaluating the results and suitability of
treatment, a Clinical Audit on anaemia correction on
unselected chronic dialysis patients (haemodialysis and
peritoneal dialysis) was set up in 2006 in order to assess
whether target haemoglobin levels and other clinical per-
formance targets such as KTV, Iron, Ferritin, Transferrin
and Transferrin saturation percentage had been obtained
and maintained throughout 2005. Some of the results
were presented in Ferrara, Italy on 6-7 October 2006 dur-
ing the Italian Interregional (Emilia Romagna, Tuscany,
Liguria) Society of Nephrology Congress.
Methods
Study design and data collection
In 2006, twenty Italian dialysis centres in 3 Italian Regions
(Emilia Romagna, Tuscany and Liguria) freely partici-
pated in a retrospective observational study for a clinical
audit on anaemia management in chronic dialysis
patients.
The main aim of the study was to evaluate, throughout
2005, how many patients reached and maintained the fol-
lowing performance targets:
• stable Haemoglobin level ≥11 ≤12 gr/dl;
￿ KT/V:>1.2 <2.0 for non diabetic HD patients;> 1.5 <2.2
for diabetic HD patients; >1.8 <2.5 for PD patients.
￿ IRON: 60-160 mcg/dl
￿ FERRITIN: 30-400 mcg/l
￿ Transferrin: 200-360 mg/dl
￿ Transferrin saturation percentage: > 25 < 50%
The secondary aim of the study was to evaluate whether:
1. The Erythropoietin doses (IU/kg/wk) were in line
with the doses suggested in the European guidelines.
2. There were significant differences between the
Erythropoietin doses (IU/kg/wk) administered to HD
patients and the doses administered to PD patients.BMC Nephrology 2009, 10:33 http://www.biomedcentral.com/1471-2369/10/33
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3. The Erythropoietin doses (IU/Kg/wk) for diabetic
patients were significantly higher than those observed
in non-diabetic patients.
4. The Erythropoietin doses (IU/Kg/wk) for patients
affected by malignancies or myeloma were signifi-
cantly different from those for non-neoplastic
patients.
5. The Erythropoietin doses (IU/Kg/wk) varied signifi-
cantly in patients on Vitamin B therapy (vitamins B12
and Calcium Folinate).
Target values were established on the basis of the recom-
mendations described in the European (2004) and Italian
(2003) guidelines. The clinical performance target for
haemoglobin was set between ≥11 ≤12 gr/dl for ≥ 85% of
the study population. The observation period covered all
patients undergoing chronic dialysis (haemodialysis and
peritoneal dialysis) from January 1st, 2005 to December
31st, 2005.
Selection of patients
Criteria for inclusion
Eligible patients had to have undergone peritoneal dialy-
sis or haemodialysis for at least three months during
2005; this included prevalent patients on 31/12/2005,
deceased patients or patients who underwent transplant
or left dialysis centres after at least three months. The only
patients excluded were, therefore, those who had under-
gone PD or HD for less than 3 months. A random sample,
statistically significant at a minimum of 95% within con-
fidence limits and proportional to the total number of
patients was taken from each participating centre. The
selection criteria were established in agreement with the
Office of Medical Statistics of S. Anna Hospital. Patients
chosen were identified with a number and, if agreed
upon, the first 3 letters of the name or surname so that all
data were essentially anonymous; an Excel® spreadsheet
for collecting data of random patients was prepared and
sent to participating centres.
The following information was collected from medical
records: Age, sex, height; start date of dialysis (for incident
patients), dialysis type; comorbidities such as diabetes,
malignancies, infections, admission to hospital (days);
causes of death; monthly body weight; KT/V; weekly
Erythropoietin doses; weekly iron therapy; therapy with B-
group vitamins (B12 and calcium folinate). Moreover, all
haemoglobin, iron, ferritin and transferrin values detected
from routine laboratory data throughout 2005 were
recorded. Data were put into a database and analysed by
the Statistic Medical Service at S. Anna Hospital. Data of
incident patients were excluded for the first two months of
dialysis treatment. Height and weight were used to calcu-
late body mass index (BMI); the weekly Erythropoietin
dose was related to the patient's body weight. For patients
receiving Darbopoietin, a conversion factor of 1 μ:200 IU
was applied.
Statistical methods
As it was a retrospective study, it was necessary to resolve
some problems.
Target values for each clinical performance parameter
were set in accordance with EBPG 2004 and Italian Guide-
lines 2003. (Table 1) However, no specific criteria (stand-
ard) for evaluating the stability of each performance target
Table 1: Target values and minimum number of determinations expected for each parameter
Parameter Minimum number of determination reports within maximum 
time span
Range considered in statistical processing
Haemoglobin At the beginning & end of the study
At least once every 30 days
≥ 11 ≤ 12 gr/dl
Iron At the beginning & end of the study
At least once every 60 days
> 15 < 180 mcg/dl
Transferrin
TSAT%: > 25 < 50
At the beginning & end of the study
At least once every 120 days
> 170 < 375 mg/dl
Ferritin At the beginning & end of the study
At least once every 60 days
> 15 < 700 mcg/l
KT/V At the beginning & end of the study
At least once every 30 days for HD patients
At least once every 120 days for DP patients
HD* range: >1.2 < 2.0
HD° range: >1.5 < 2.2
DP range: > 1.8 <2,5
*non diabetic patients
° diabetic patientsBMC Nephrology 2009, 10:33 http://www.biomedcentral.com/1471-2369/10/33
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in relation to the length of the dialysis treatment have yet
been identified. As patients were undergoing dialysis for
varying periods of time and thus the likelihood that the
values would consistently fall within the accepted ranges
would decrease proportionally over time, three different
patient classes were created in relation to the months of
dialysis undertaken during 2005 (Class 1: from 1 to 4
months, Class 2: from 5 to 8 months, Class 3: from 9 to
12 months). Commencing with the assumption that a sin-
gle value noted outside the stated limits could have a dif-
ferent significance when observed over periods of
different lengths, we set arbitrary but reasonable specific
intervals of tolerance for each class in relation to the
months of dialysis received, in order to evaluate whether
the patients maintained the target over time (Table 2).
Data from each patient was therefore considered on the
basis of: total number of determinations expected for each
considered parameter and value of each determination vs.
established ranges for each parameter.
The first step was to see whether each patient had the min-
imum expected number of determinations for each
parameter within the set time intervals: for patients who
received 1 to 4 months of dialysis (class 1), the number of
determinations for each parameter had to be within the
expected range for 99% of the time; for those who
received 5 to 8 months of dialysis (class 2), the number of
determinations had to be within the expected range for
more than 90%; and finally, for those patients who
received 9 to 12 months of dialysis (class 3), the number
of determinations had to be within the range for more
than 80% of the time. This was necessary because whilst
the majority of Centres noted haemoglobin values at least
once a month, 5 centres noted the values of long term
dialysis patients only every two or three months (this was
however taken into consideration in the 2003 Italian
Guidelines). If the number of determinations was suffi-
cient, the percentage of the expected determinations
which maintained the target was evaluated. The same per-
centages were used to judge the maintenance of target val-
ues over time, i.e. the data permanence. As a result of this
process, based on the percentage of presence and perma-
nence of the data within the limits, at least three ranges of
cases were highlighted, and four "permanence" groups
were thus created: "entire permanence" (Group 3), "par-
tial permanence" (Group 2), "limited permanence"
(Group 1) and "insufficient permanence" (Group -1). In
this specific study, only two groups of cases were consid-
ered: cases that were always within the set target (Group 3
"entire permanence") and cases that did not reach the
planned target (Group -1 "insufficient permanence"); the
number of cases belonging to other groups was negligible.
Subsequently, a second stage was set up to answer issues
which arose from the first set of results. Parametric/non-
parametric procedures such as ANOVA or analogous non-
parametric ones: 1 way Analysis of Variance or Notched
"Box & Whiskers" test ('BW'), were used to evaluate
whether the Erythropoietin dose (IU/Kg/week) was signif-
icantly different:
- between the two dialysis techniques (haemodialysis vs.
peritoneal dialysis)
- for diabetic patients with respect to non-diabetic patients
- for patients affected by malignancies or myeloma with
respect to non-neoplastic patients.
- for patients on Vitamin B therapy (vitamins B12 and Cal-
cium Folinate);
Simple linear regression was used to evaluate possible
relationships between Erythropoietin dose (IU/Kg/wk) in
relation to haemoglobin values and to hospital admission
for more than 3 days.
Results
In a total study population of 3283 patients, 391 subjects
were excluded; of the remaining 2892 eligible patients,
Table 2: Criteria adopted to judge the maintenance of target values over time
Data presence* %
Data permanence‡ %
Class 1 from 1 to 4 months of 
dialysis
Class 2 from 5 to 8 months of 
dialysis
Class 3 from 9 to 12 months of 
dialysis
Group 3 "entire permanence" >= 99% >= 90% >= 80%
Group 2 "partial permanence" >= 85% <90% >= 75% <80%
Group 1 "limited permanence" >= 80% <85% >= 70% <75%
Group -1 "insufficient 
permanence"
<99% < 80% <70%
Percentages of data presence and data permanence within the set limits per parameter in relation to the length of the dialysis treatment
*total number of determinations expected for each considered parameter
‡value of each determination vs. established ranges for each parameter.BMC Nephrology 2009, 10:33 http://www.biomedcentral.com/1471-2369/10/33
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540 were selected for the study. Data from 4 selected
patients were excluded as they were deemed insufficient
for statistical processing, therefore data from 536 patients
were subjected to statistical analysis.
Sample characteristics: 461 patients underwent haemodial-
ysis and 70 patients underwent peritoneal dialysis for the
entire period of observation; 5 patients were subjected to
both dialysis techniques; 67 patients suffering from diabe-
tes and 44 from malignancies or myeloma, 47 patients died
during the observation period. The mean age (male and
female) was 65.14; however, the mean age in two centres
was more than 71 years. The mean haemoglobin concen-
tration for the whole population was 11.3 gr/dl (SD 0.91).
Mean values of clinical performance targets for patients,
who maintained the target for the whole period and all
mean values for each parameter in all cases, were obtained
as follows (Table 3). All patients (23) who maintained the
haemoglobin target over time also held stable iron values
(mean value 60.83 mcg/dl) but did not maintain stable
Transferrin values or Transferrin saturation percentage.
Out of 23 patients, 1 patient with myeloma and 3 patients
suffering from malignancies maintained stable haemo-
globin levels over time.
Erythropoietin doses were significantly lower for the peri-
toneal dialysis technique. (P < 0.0003) (Figure 1) but did
not vary significantly in relation to diabetes status or use
of B12 vitamin and calcium folinate.
Erythropoietin doses (IU/Kg/wk) in patients suffering
from malignancies or myeloma steadily increased in the
group of cancer patients in comparison to the non-neo-
plastic group but the difference was not statistically signif-
icant (Figure 2).
A significant decrease in Erythropoietin doses (IU/Kg/wk)
was observed with the increase of haemoglobin values (P
< 0.000) (Figure 3).
No relationship was found between Erythropoietin doses
and hospital admission of more than 3 days, owing to
very few cases of hospital admissions of over 4 days.
As the mean transferrin value was low in a large percent-
age of patients, a possible relationship between BMI and
Table 3: Results
Mean values for patients who maintained target for the whole 
period
Mean values for the whole sample
Parameter Total n° of 
cases
Mean value Mean SD Target 
maintained 
(cases number)
Target 
maintained %
Mean value SD Cases > 0
HAEMOGLOBIN
(g/dl)
536 11.43 0.42 23 4.3 11.3 0.91 536
KTV HD ^ 461 1.46 0.7 281 61 1.37 0.06 441
KT/V PD^° 70 2.1 0.02 22 31.4 2.02 0.01 51
IRON
mcg/dl
536 59.79 16.76 511 95 59.75 17.4 531
FERRITIN
mcg/l
536 250.23 104.07 381 71.1 397.77 148.8 532
TRANSFERRIN
mg/dl
536 216.83 19.5 240 44.8 187.65 20.42 488
TRANSFERRIN 
SATURATION %
536 34.33 6.56 45 8.4 24.08 7.63 484
Erythropoietin 
dose
IU/Kg/wk
536 155.21 41.54 400 74.6 143.41 40.87 457
"zero" values are excluded from the calculation of averages.
^ Cases of patients undergoing both dialysis techniques during the observation period were excluded.
° Not all centres provided data.BMC Nephrology 2009, 10:33 http://www.biomedcentral.com/1471-2369/10/33
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transferrin was assessed; there appeared to be a rise in
transferrin values in relation to increase of BMI (P <
0.018). However, further verifications in terms of higher
case numbers and revision of values in selected cases
would be needed (Figure 4).
The Transferrin saturation percentage did not show signif-
icant variations in relation to BMI.
Discussion
Reaching and maintaining the standard proposed by the
guidelines for long term anaemia treatment in unselected
populations of dialysis patients continues to be a very dif-
ficult goal to achieve in clinical practice.
Currently, the guidelines recommend reaching and main-
taining haemoglobin target values of 11 to 12 gr/dl for the
majority of patients in chronic dialysis; the previously
(2003) proposed standard requires 85% or more of
patients to reach this target.
As the mean value of each parameter calculated during
this study did not demonstrate whether the patients had
maintained the target over time, a set of arbitrary rules, in
relation to the length of dialysis, was created in order to
judge the real permanence within the stated limits: the
present study, for example, took into account the groups
of patients with values constantly within and outside the
limits. The adopted method to evaluate the stability of
each parameter was arbitrarily set following the European
and Italian guidelines, allowing the evaluation of every
patient undergoing chronic dialysis during the year in
relation to the length of dialysis period (an abstract
including early results from this work was previously pub-
lished [32]).
The method could be criticized because of the percentage
of tolerance allowed for defining the maintenance of the
target for each parameter, because of the time interval
used to define classes of patients or because of the time
intervals stated for defining stable Hb values of incident
patients.
A positive point, however, is that if it were necessary to
modify the fixed limits for each parameter, the percent-
ages could be recalculated without difficulty.
Some factors may have had a negative impact on the
results:
1 The decision to not choose specific patients for the pop-
ulation in order to obtain general information.
2 The inclusion of patients who died during the study and
patients who underwent less than 6 months of dialysis, as
well as the inclusion of patients with malignancies or
myeloma.
Erythropoietin doses in relation to dialysis technique Figure 1
Erythropoietin doses in relation to dialysis technique. 
Cases of patients undergoing both dialysis techniques during 
the observation period were excluded. CI: Confidence Inter-
val. HD Patients n. 398: Mean Erythropoietin dose IU/Kg/wk: 
150.21. (CI: 95%, 139.47:160.94). PD Patients n. 54: Mean 
Erythropoietin dose IU/Kg/wk: 92.13. (CI: 95%, 
63.99:122.27). P < 0.0003
Erythropoietin doses in patients suffering from malignancies  or myeloma vs. non-neoplastic patients Figure 2
Erythropoietin doses in patients suffering from 
malignancies or myeloma vs. non-neoplastic patients. 
Patients who developed malignancies or myeloma during the 
observation period were excluded. CI: Confidence Interval. 
Patients with Malignancies/myeloma n. 44: Mean Erythropoie-
tin (IU/Kg/wk): 206.75 (CI 95%, 174.70: 238.79). Patients 
without Malignancies/myeloma n. 413: Mean Erythropoietin 
(IU/Kg/Wk): 136.66 (CI 95%, 126.20: 147.12). P < 0.0001. 
The averages and medians of Erythropoietin doses seem con-
sistently higher in the group of patients with cancer or mye-
loma but the difference evaluated by the non-parametric 
method was not statistically significant.BMC Nephrology 2009, 10:33 http://www.biomedcentral.com/1471-2369/10/33
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3 The fact that the population was primarily made up of
elderly patients (mean age greater than 65 years), several
of whom had limited life expectancy.
This study shows that a very limited percentage of patients
maintained the target values for Haemoglobin (4.3%)
and Transferrin saturation (TSAT %) (8.4%) over time.
The percentage is much lower than the one observed by
other authors [16,22,26,29,33] on incident or prevailing
patients on haemodialysis.
These results are not, however, strictly comparable, due to
the different methods used when carrying out the studies
and also due to the different characteristics of popula-
tions; results regarding HB targets are similar to those
(6.5%) presented by Ebben [14] in HD patients over a six
month period.
The mean value for Haemoglobin for the whole popula-
tion of patients (11.3 gr/dl) does not differ much from the
value observed in the population which maintained the
target for the whole observation period (11.43 gr/dl).
The mean dose used in subjects who always remained
inside target levels was 155.21 IU/kg/wk, versus a mean
dose of 143.41 IU used in subjects who always remained
outside target levels; the mean HB value leads us to
assume that the majority of patients always presented HB
levels under 11 gr/dl; transferrin values were stable in
44.8% of cases, while transferrin saturation values were
very low, even in presence of iron values that were on tar-
get in 95% of cases: this data suggests the need to better
evaluate the nutritional status and associated inflamma-
tion pathologies.
Moreover, the time required to reach target haemoglobin
values for incident patients could have been greater than
three months, as this limit was in fact modified by EBPG
2004 and by the Italian Guidelines 2007.
There is now clearly a need to identify precise criteria to
evaluate, in clinical practice, the stability of clinical per-
formance targets as proposed by the guidelines.
Using a "mean value" criteria does not define which
patients, in the considered population, reach and main-
tain a standard result over time, thus not enabling one to
evaluate if the maintenance of the objective ensures that
every patient has a reduced risk of mortality and an
improvement in quality of life. The definition of clinical
stability criteria is very important when evaluating results
gathered during delivery of care to complex patient
groups; this also leads to a better use of resources.
Conclusion
Clinical performance targets were obtained and main-
tained in different proportions throughout 2005 in the
study population.
Data analysis shows that only a small percentage of
patients maintained the Haemoglobin target over time
and that it is quite clearly a major deviation from the
standard set by the guidelines. Transferrin values for many
patients for all or part of the observation period are low or
very low, suggesting the need of further investigations on
the nutritional status or associated inflammatory diseases.
Erythropoietin doses in dependence on HB values Figure 3
Erythropoietin doses in dependence on HB values. 
Degrees of freedom: 456. Regression coefficient: -57.07. 
Correlation coefficient (R): - 0.49. Coefficient of determina-
tion: 24.48. Regression significance: P < 0.000. The regres-
sion is greatly significant and the same correlation coefficient 
is high due to the reduced amount of points distant from the 
straight line.
Transferrin Values in dependence on BMI Figure 4
Transferrin Values in dependence on BMI. Degrees of 
freedom: 484. Regression coefficient: 1.09. Correlation coef-
ficient (R): 0.107. Coefficient of determination: 1.15. Regres-
sion significance: P < 0.018.BMC Nephrology 2009, 10:33 http://www.biomedcentral.com/1471-2369/10/33
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The very low percentage of patients maintaining stable
Transferrin saturation values despite high percentage of
Iron stable values calls for further studies and evaluations.
If the target maintenance is to be regarded as an important
goal of care quality, it might be necessary to revise the
standard (equal or more than 85%) proposed by the
guidelines, especially regarding Haemoglobin, for which
the target has to be maintained within narrow ranges.
Simple methods should be identified to enable the verifi-
cation in clinical practice of the stability over time of clin-
ical performance targets recommended in the guidelines.
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